ITGAM and peritonitis: While a general blockade of Mac-1 is deemed too dangerous in the clinical setting as the molecule interacts with a multitude of immunological targets (e.g., ICAM-1 and RAGE), and genetic mutations that impair Mac-1 signaling cause immune defects (leucocyte adhesion deficiency), the specific blockade of CD40L-Mac-1 interaction with the antibody anti-M7 was able to successfully dampen inflammation in an acute model for peritonitis without causing immunosuppression [101].